PFE disclosed on today’s 3Q15 CC that the FDA issued a CRL for the 351(k) application submitted by HSP (prior to PFE’s buyout). PFE said it would resubmit the aBLA with additional data.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.